Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031275 | 1.00 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13688280 | 0.82 | FFAR3 (0.41) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9784921 | 0.81 | NPSR1 (0.32) | FFAR3 | |
| SCHEMBL9639839 | 0.81 | NPSR1 (0.32) | FFAR3 | |
| SCHEMBL11522215 | 0.79 | FFAR3 (0.35) | FFAR3ALDH1A1 | |
| SCHEMBL6135816 | 0.78 | CYP2C19 (0.39) | FFAR3ALDH1A1 | |
| SCHEMBL21950869 | 0.78 | CYP2C19 (0.39) | FFAR3ALDH1A1 | |
| SCHEMBL8615746 | 0.78 | — | — | |
| SCHEMBL8467424 | 0.78 | — | — | |
| SCHEMBL21950923 | 0.76 | FFAR3 (0.31) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| EP-3292104-A1 | CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Astrazeneca AB (SE) | 2018-03-14 | — | — | EP | disclosed |
| US-20170216283-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| US-9657001-B2 | Compounds and uses | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| WO-2016177845-A1 | CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2-SCIENCE APS (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-1592436-A4 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | KIMBERLY CLARK CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1592436-A2 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | Kimberly-Clark Worldwide, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004060907-A2 | COMPOUNDS THAT BIND P2Y2 OR P2Y1 RECEPTORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6538006-B1 | N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment of | PHARMACIA CORPORATION | 2003-03-25 | — | — | US | disclosed |
| US-5510378-A | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0007128-B1 | DERIVATIVES OF 3-AZABICYCLO(3.1.0)HEXANE AND PROCESSES FOR THEIR PREPARATION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-02-16 | — | — | EP | disclosed |
| EP-0007128-A1 | Derivatives of 3-azabicyclo(3.1.0)hexane and processes for their preparation | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216283-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | FFAR3 492/4885HDAC3 2409/4885HDAC1 2541/4885 |
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2RY2, P2RY1, P2RY11 | FFAR3 502/4885HDAC3 4592/4885HDAC1 4808/4885 |
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | FFAR3 4391/4885HDAC3 393/4885HDAC1 183/4885 |
| US-20160326143-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | FFAR3 492/4885HDAC3 2409/4885HDAC1 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.